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LAMPIRAN 1 : PERHITUNGAN DOSIS KONVERSI
1,2 Dimethylhidrazine
Dosis  30 mg/kgBB/minggu
Berat 20 gram = 6mg/ekor/minggu
Jumlah pemberian 16 kali
TOTAL = 16 kali x 6 mg x 40 ekor = 3.840 mg
5FU-Leucovorin (Rosswell Park Regiment)
Dosis pemberian kemoterapi (Konstanta konversi = 0.018)
BSA Tikus : BB Tikus = 200 gram = 0,2 kg - Panjang Badan Tikus : 20 cm
BSA = 10.5 (wt. in grams)2/3   = 0.03 m2
Dosis Leucovorin pada Tikus = 500 mg/m2 x 0.018 x 0.03 m2 = 0.27 mg
Dosis 5FU pada Tikus = 500 mg/m2 x 0.018 x 0.03 m2 = 0.27 mg
P. macrocarpa
Dosis ekstrak = 0.495 mg/hari
Konsentrasi larutan = 0.495 mg/ml
Jumlah tikus = 16 ekor
Lama perlakuan = 49 hari
Kebutuhan ekstrak Phaleria macrocarpa = 0.495 mg/ekor/hr x 16 ekor x 49 
hari = 388.08 mg =784 cc
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LAMPIRAN 2. HASIL PENGAMATAN DENSITAS SEL NK DAN EKSPRESI
   GRANZYM B
Tabel 9: Tabulasi data densitas Sel NK
Kel La1 La2 La3 La4 La5 Rataa Lb1 Lb2 Lb3 Lb4 Lb5 ratab rataNK
K 1 6 4 6 5 6 5.4 6 6 6 5 6 5.8 5.6
K 2 5 6 5 4 6 5.2 6 4 6 5 6 5.4 5.3
K 3 6 6 5 3 5 5 5 6 6 6 5 5.6 5
K 4 4 4 5 6 5 4.8 4 5 7 6 5 5.4 5.1
K 5 4 5 4 5 4 4.4 5 4 4 5 4 4.4 4.4
K 6 6 7 6 6 7 6.4 7 6 5 6 7 6.2 6.3
P1 1 10 7 10 10 8 9 8 9 10 10 8 9 9
P1 2 8 9 8 6 10 8.2 9 9 8 7 10 8.6 8.4
P1 3 8 8 8 8 8 8 9 8 7 8 8 8.8 8
P1 4 8 8 10 8 8 8.4 8 9 9 10 9 9 8.7
P1 5 9 10 8 8 10 9 8 10 8 8 9 8.6 8.8
P1 6 10 9 10 8 10 9.4 10 9 9 8 10 9.2 9.3
Tabel 10: Tabulasi data ekspresi granzym B
Kel La1 La2 La3 La4 La5 Rataa Lb1 Lb2 Lb3 Lb4 Lb5 ratab rataGR
K 1 10 8 11 10 8 9.4 10 9 10 9 9 9.4 9.4
K 2 12 12 11 9 10 10.8 11 12 10 11 10 10.8 10.8
K 3 12 10 10 8 10 10 11 10 10 9 10 10 10
K 4 10 10 10 12 12 10.8 11 10 11 11 11 10.8 10.8
K 5 9 11 11 10 9 10 9 11 11 10 9 10 10
K 6 11 9 10 11 11 10.4 12 9 10 11 10 10.4 10.4
P1 1 14 12 8 10 13 11.4 14 11 9 11 12 11.4 11.4
P1 2 12 10 10 14 10 11.2 12 11 10 13 10 11.2 11.2
P1 3 10 12 12 10 10 10.8 11 11 12 10 10 10.8 10.8
P1 4 12 10 13 10 11 11.2 12 12 13 12 11 11.2 11.2
P1 5 12 10 14 12 11 11.8 12 11 13 11 12 11.8 11.8
P1 6 13 12 10 12 12 11.8 12 12 11 13 11 11.8 11.8
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LAMPIRAN 3. FOTO PENELITIAN
Gambar 12. Gambar  hewan coba sedang diinduksi 1,2-dimethylhidrazine (kanan)
Gambar 13. Gambar hewan coba sedang mendapat perlakuan (kiri)
Gambar 14. Gambaran makroskopis adenokarsinoma kolorektalyang sudah 
          diisolasi ( kanan dan kiri)
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N Percent N Percent N Percent
Sel_NK  * Kelompok 12 100.0% 0 .0% 12 100.0%
EXPLORE
RATA DENSITAS SEL_NK
Kelompok N Mean Median Minimum Maximum Sum Variance Std. Deviation
Kontrol 6 5.283 5.200 4.4 6.3 31.7 .406 .6369
P1 6 8.700 8.750 8.0 9.3 52.2 .208 .4561




Statistic df Sig. Statistic Df Sig.
Sel_NK Kontrol .162 6 .200* .977 6 .936
P1 .167 6 .200* .987 6 .980
a. Lilliefors Significance Correction
*. This is a lower bound of the true significance.
Test of Homogeneity of Variance
Levene Statistic df1 df2 Sig.
Sel_NK Based on Mean .344 1 10 .570
Based on Median .328 1 10 .579
Based on Median and with 
adjusted df
.328 1 8.765 .581
Based on trimmed mean .344 1 10 .571
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RATA –RATA DENSITAS SEL NK KELOMPOK KONTROL
RATA –RATA DENSITAS SEL NK KELOMPOK PERLAKUAN
.
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BOX PLOT  KELOMPOK KONTROL DAN PERLAKUAN
UJI KOMPARASI DENGAN INDEPENDENT T TEST
Levene's Test 
for Equality 
of Variances t-test for Equality of Means
95% Confidence 
Interval of the 
Difference







Sel_NK Equal variances assumed .344 .570 -10.683 10 .000 -3.4167 .3198 -4.1292 -2.7041






N Percent N Percent N Percent






Statistic df Sig. Statistic df Sig.
Granzyme_B Kontrol .185 6 .200* .913 6 .459
P1 .201 6 .200* .912 6 .452
a. Lilliefors Significance Correction
*. This is a lower bound of the true significance.
Test of Homogeneity of Variance
Levene Statistic df1 df2 Sig.
Granzyme_B Based on Mean .952 1 10 .352
Based on Median .899 1 10 .365
Based on Median and with 
adjusted df
.899 1 9.648 .366
Based on trimmed mean .950 1 10 .353
RATA EKSPRESI GRANZYM B
Kelompok N Mean Median Minimum Maximum Sum Variance Std. Deviation
Kontrol 6 10.233 10.200 9.4 10.8 61.4 .295 .5428
P1 6 11.367 11.300 10.8 11.8 68.2 .151 .3882
Total 12 10.800 10.800 9.4 11.8 129.6 .553 .7435
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RATA –EKSPRESI GRANZYM B KELOMPOK KONTROL
RATA –EKSPRESI GRANZYM B KELOMPOK PERLAKUAN
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BOX PLOT  KELOMPOK KONTROL DAN PERLAKUAN
UJI KOMPARASI DENGAN INDEPENDENT T TEST
Levene's Test 
for Equality of 
Variances t-test for Equality of Means
95% 
Confidence 
Interval of the 
Difference







Granzyme_B Equal variances assumed .952 .352 -4.160 10 .002 -1.1333 .2724 -1.7404 -.5263
Equal variances not 
assumed
-4.160 9.053 .002 -1.1333 .2724 -1.7491 -.5176
UJI KORELASI DENGAN UJI PEARSON
Sel_NK Granzyme_B
Sel_NK Pearson Correlation 1 .819**
Sig. (2-tailed) .001
N 12 12
Granzyme_B Pearson Correlation .819** 1
Sig. (2-tailed) .001
N 12 12
**. Correlation is significant at the 0.01 level (2-tailed).
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LAMPIRAN 5.  ETHICAL CLEARANCE
